As Dorian Lpg LTD (LPG) Shares Declined, Phoenix Investment Adviser Boosted Its Position; Celgene (CELG) Shares Declined While Polen Capital Management Cut Position

June 13, 2018 - By Marie Mckinney

Celgene Corporation (NASDAQ:CELG) Logo

Polen Capital Management Llc decreased its stake in Celgene Corp (CELG) by 99.93% based on its latest 2018Q1 regulatory filing with the SEC. Polen Capital Management Llc sold 5.11 million shares as the company’s stock declined 18.51% with the market. The institutional investor held 3,743 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $334,000, down from 5.11 million at the end of the previous reported quarter. Polen Capital Management Llc who had been investing in Celgene Corp for a number of months, seems to be less bullish one the $56.38 billion market cap company. The stock increased 0.41% or $0.32 during the last trading session, reaching $77.79. About 3.32M shares traded. Celgene Corporation (NASDAQ:CELG) has declined 32.65% since June 13, 2017 and is downtrending. It has underperformed by 45.22% the S&P500. Some Historical CELG News: 09/04/2018 – cafepharma: Celgene on biotech hunt with Agios, Jounce in crosshairs: FT: After a tough few months for the Big Biotech; 16/05/2018 – Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology (ASCO) Scientific Sessions; 09/04/2018 – CELG: Celgene M&A targets may include Agios, Jounce, FT reports; 13/03/2018 – MERCK & CO INC – SBLA FOR KEYTRUDA IS BASED IN PART ON DATA FROM PHASE 2 KEYNOTE-158 TRIAL; 13/03/2018 – Merck Gets FDA Priority Review for Keytruda sBLA in Advanced Cervical Cancer; 26/03/2018 – BRISTOL-MYERS SQUIBB CO – CHMP RECOMMENDATION OF OPDIVO WILL NOW BE REVIEWED BY EUROPEAN COMMISSION; 09/04/2018 – The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Celgene; 09/04/2018 – Keytruda is already approved to treat several forms of cancer, including advanced melanoma. The drug racked up $3.81 billion in revenue in 2017; 15/05/2018 – The PM bureau: $CELG, Fidelity backed – Seattle’s Nohla closes $45M to bring novel stem cell treatment for leukemia to late-stage trials; 04/05/2018 – CELGENE DOESN’T SEE TRIAL THIS YR IN DR. REDDY’S PATENT MATTER




Phoenix Investment Adviser Llc increased its stake in Dorian Lpg Ltd (LPG) by 43.68% based on its latest 2018Q1 regulatory filing with the SEC. Phoenix Investment Adviser Llc bought 43,532 shares as the company’s stock declined 8.18% with the market. The hedge fund held 143,191 shares of the marine transportation company at the end of 2018Q1, valued at $1.07M, up from 99,659 at the end of the previous reported quarter. Phoenix Investment Adviser Llc who had been investing in Dorian Lpg Ltd for a number of months, seems to be bullish on the $462.35 million market cap company. The stock decreased 0.36% or $0.03 during the last trading session, reaching $8.39. About 123,265 shares traded. Dorian LPG Ltd. (NYSE:LPG) has declined 15.84% since June 13, 2017 and is downtrending. It has underperformed by 28.41% the S&P500. Some Historical LPG News: 04/05/2018 – DORIAN LPG – UPGRADING CO’S VLGCS’ MAIN ENGINES TO DUAL FUEL TECHNOLOGY USING LPG AS FUEL IN ANTICIPATION OF REGULATIONS TO REDUCE SULPHUR EMISSIONS; 21/03/2018 – DORIAN LPG LTD – ENTERED INTO A $70.0 MLN SALE AND BAREBOAT CHARTER ARRANGEMENT FOR CORVETTE; 21/03/2018 – DORIAN LPG ENTERS INTO $70M SALES/BAREBOAT CHARTER ARRANGEMENT; 29/05/2018 – Shipper BW LPG offers to buy Dorian LPG in $1.1 bln deal; 21/03/2018 – Dorian LPG Ltd. Announces Third Japanese Financing; 29/05/2018 – BW LPG PROPOSES TO COMBINE W/ DORIAN IN $ $1.1B TRANSACTION; 04/05/2018 – DORIAN LPG IN MOU WITH HYUNDAI GLOBAL SERVICE ON UPGRADES; 29/05/2018 – DORIAN LPG SAYS BOARD WILL REVIEW BW’S PROPOSAL; 29/05/2018 – BW LPG Proposes to Combine With Dorian in All-Stk Transaction Valued at USD $1.1 B; 29/05/2018 – DORIAN LPG’S BOARD WILL REVIEW BW’S PROPOSAL

Phoenix Investment Adviser Llc, which manages about $1.28B and $56.61 million US Long portfolio, decreased its stake in Autoliv Inc (NYSE:ALV) by 7,400 shares to 2,600 shares, valued at $379,000 in 2018Q1, according to the filing. It also reduced its holding in Navigator Holdings Ltd (NYSE:NVGS) by 57,000 shares in the quarter, leaving it with 59,764 shares, and cut its stake in Tenet Healthcare Corp (NYSE:THC).

Among 4 analysts covering Dorian LPG (NYSE:LPG), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Dorian LPG had 6 analyst reports since December 18, 2015 according to SRatingsIntel. As per Tuesday, March 22, the company rating was downgraded by UBS. On Wednesday, March 1 the stock rating was upgraded by Pareto to “Hold”. The firm earned “Market Perform” rating on Tuesday, January 26 by Wells Fargo. The stock of Dorian LPG Ltd. (NYSE:LPG) earned “Overweight” rating by JP Morgan on Friday, December 18. UBS maintained Dorian LPG Ltd. (NYSE:LPG) on Monday, November 13 with “Neutral” rating.

More recent Dorian LPG Ltd. (NYSE:LPG) news were published by: Nasdaq.com which released: “Mid-Morning Market Update: Markets Open Higher; Michael Kors Beats Q4 Estimates” on May 30, 2018. Also Businesswire.com published the news titled: “BW LPG Proposes to Combine with Dorian in All-Stock Transaction Valued at USD $1.1 Billion” on May 29, 2018. Globenewswire.com‘s news article titled: “Report: Exploring Fundamental Drivers Behind ServisFirst Bancshares, Iovance Biotherapeutics, Inc., MarineMax …” with publication date: May 29, 2018 was also an interesting one.

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on July, 26. They expect $1.87 earnings per share, up 11.31% or $0.19 from last year’s $1.68 per share. CELG’s profit will be $1.36 billion for 10.40 P/E if the $1.87 EPS becomes a reality. After $1.61 actual earnings per share reported by Celgene Corporation for the previous quarter, Wall Street now forecasts 16.15% EPS growth.

Polen Capital Management Llc, which manages about $5.08B and $14.09B US Long portfolio, upped its stake in Alphabet Inc by 21,615 shares to 990,728 shares, valued at $1.02 billion in 2018Q1, according to the filing. It also increased its holding in Medtronic Plc (NYSE:MDT) by 28,460 shares in the quarter, for a total of 50,827 shares, and has risen its stake in Align Technology Inc (NASDAQ:ALGN).

Since February 8, 2018, it had 2 insider buys, and 5 sales for $5.91 million activity. LOUGHLIN JAMES J sold $1.40 million worth of stock. 1,208 shares valued at $99,784 were bought by Alles Mark J on Tuesday, May 8. KAPLAN GILLA sold 18,500 shares worth $1.77 million. 13,370 shares were sold by MARIO ERNEST, worth $1.26 million.

Among 35 analysts covering Celgene Corporation (NASDAQ:CELG), 20 have Buy rating, 1 Sell and 14 Hold. Therefore 57% are positive. Celgene Corporation had 150 analyst reports since July 21, 2015 according to SRatingsIntel. On Thursday, June 1 the stock rating was maintained by Mizuho with “Buy”. On Tuesday, October 17 the stock rating was maintained by BMO Capital Markets with “Outperform”. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Wednesday, April 4 by RBC Capital Markets. The firm has “Buy” rating given on Thursday, January 7 by SunTrust. The stock has “Buy” rating by Suntrust Robinson on Friday, April 29. The stock of Celgene Corporation (NASDAQ:CELG) earned “Buy” rating by Cantor Fitzgerald on Thursday, July 27. The firm earned “Overweight” rating on Thursday, October 1 by JP Morgan. The stock has “Buy” rating by Leerink Swann on Wednesday, December 13. As per Friday, June 16, the company rating was upgraded by Leerink Swann. The rating was maintained by SunTrust with “Buy” on Friday, October 20.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Seekingalpha.com which released: “5 Reasons Why Celgene Will Recover” on June 01, 2018, also Fool.com with their article: “Better Buy: Biogen Inc. vs. Celgene” published on June 03, 2018, Seekingalpha.com published: “Acceleron: Luspatercept New Data Is A Buy Signal” on June 07, 2018. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Seekingalpha.com and their article: “Celgene: Still (Looks) Appealing” published on May 21, 2018 as well as Seekingalpha.com‘s news article titled: “Will ‘Public Shaming’ Sink Celgene?” with publication date: May 21, 2018.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: